Long-term effects of Helicobacter pylori eradication in Mongolian gerbils.
BACKGROUND
In this study, to clarify whether Helicobacter pylori eradication alters the course of the development of gastric mucosal changes in the stomach, we examined the long-term effects of H. pylori eradication on H. pylori-inoculated gerbils.


METHODS
A total of 40 H. pylori-inoculated gerbils were randomized and subjected, at 22 months after inoculation, to eradication treatment with dual therapy of omeprazole plus clarithromycin, or with therapy with a novel quinolone compound, Y-34867, alone. The animals were killed at the start of administration (control group) or at 8 months after the completion of therapy (vehicle or eradication-treatment groups).


RESULTS
Severe histopathological changes in the gastric mucosa were observed in all H. pylori-inoculated gerbils at the start of administration. At 8 months after completion of therapy, the frequency of gastritis, erosion, intestinal metaplasia, and gastric carcinoid in the eradication therapy groups was markedly reduced compared with that in the control and vehicle groups. Values for anti- H. pylori IgG titer, bacterial counts, and gastrin also decreased significantly.


CONCLUSIONS
These results suggest that H. pylori eradication may have had a therapeutic effect not only on gastritis, erosion, and gastric ulcer but also on glandular atrophy, intestinal metaplasia, and gastric carcinoid.
Hirayama
Fumihiro
F
Protein Research Laboratories, Mitsubishi Pharma Corporation, 2-25-1 Shodai-ohtani, Hirakata 573-1153, Japan.
Takagi
Shiro
S
Yokoyama
Yoshito
Y
Yamamoto
Katsuhiro
K
Iwao
Eiji
E
Haga
Keiichiro
K
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000890:Anti-Infective Agents / Q000008:administration & dosage; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D000907:Antibodies, Bacterial / Q000032:analysis; D017291:Clarithromycin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005753:Gastric Mucosa / Q000473:pathology*; D005756:Gastritis / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology*; D005849:Gerbillinae; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D016480:Helicobacter pylori / Q000276:immunology / Q000302:isolation & purification; D008297:Male; D009853:Omeprazole / Q000008:administration & dosage; D015363:Quinolones / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000897:Anti-Ulcer Agents; D000907:Antibodies, Bacterial; D015363:Quinolones; C471634:Y34867; D017291:Clarithromycin; D009853:Omeprazole